Compare Vanguard Information Technology Index Fund ETF (VGT) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Information Technology Index Fund ETF vs 22nd Century Group Inc — how do they compare? Vanguard Information Technology Index Fund ETF trades at $128.1 (market cap $170.20B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 273778.7× 22nd Century Group Inc's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Information Technology Index Fund ETF for 129 Days and 22nd Century Group Inc for 32 Days on average.
| VGT | XXII | |
|---|---|---|
Market Cap | $170.20B | $621.67K |
Volume | 5,132,883 | 45,625 |
52-Week High | $129.79 | $483.00 |
52-Week Low | $83.59 | $0.80 |
Typical Hold Time | 129 Days | 32 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VGT trades at $127.78, down 1.23% today but maintains a bullish technical outlook with strong moving average signals. The ETF, focused on U.S. technology stocks, has delivered exceptional historical returns, averaging over 17% annually. Recent news highlights its low expense ratio and concentration in tech giants like Nvidia, Apple, and Microsoft. A dividend of $0.15 is scheduled for September 2026.
Long-term growth prospects remain favorable given tech sector dominance and AI momentum, but risks include sector concentration, valuation concerns, and potential AI slowdown. Institutional ownership is increasing, with firms like Baird Financial raising stakes significantly. The current price near pivot point resistance at $128 suggests near-term consolidation before potential breakout.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
